



Fortnightly TAG Mail – resources list

18th July 2024

NSW TAG ACTIVITIES

Invitation to participate in survey: Protocols for critical medicines in NSW public facilities

To be completed by the healthcare professionals familiar with a hospital's/district's/service's protocols for critical care medicine (who may wish to answer as a group of healthcare professionals). It should take no more than 10-15 minutes. Survey closes **24th August 2024**.

Survey Link: <https://www.surveymonkey.com/r/PJZ3989>

New open email discussions

-Ongoing infliximab for immune therapy colitis Closes 26th July 2024

Recently completed email discussions

-Feedback for TGA Proposed Updates to Medicine Labelling Rules.

-Implementation of the Guiding Principles for Transition of Young People on Complex and/or Costly Medicines from Paediatric to Adult Care.

Contact Sasha Bennett at sasha.bennett@svha.org.au for further information about any email discussions, publications or upcoming meetings.

EDITOR'S PICKS

AJHSP: Mapping the next steps for critical care pharmacists - [link](#)

BJCP: Optimizing anticoagulation therapy for in-hospital patients on direct oral anticoagulants - [link](#)

BJCP: Economic evaluations of therapeutic drug monitoring interventions in acute hospital-based settings- [link](#)

BMJ: New and emerging treatments for major depressive disorder - [link](#)

BMJ QS: -Frequency and preventability of adverse drug events in the outpatient setting - [link](#)

BMJ QS: Components of pharmacist-led medication reviews and their relationship to outcomes- [link](#)

EHJ: Safety of treating acute pulmonary embolism at home- [link](#)

EJHP: Cost-effectiveness of preoperative pharmaceutical care consultations: a 5-year analysis - [link](#)

EJHP: Risk assessment of clinical trial protocols: a tool for hospital pharmacists to reduce human error in experimental drug management - [link](#)

IJCP: Impact of medicine shortages on hospital practice: role of a multidisciplinary medicine shortages team - [link](#)

IJCP: The impact of codeine rescheduling on non-opioid analgesic use by people who regularly use codeine: a prospective cohort study - [link](#)

IJCP: Cost avoidance of pharmacist-led deprescribing using STOPPFrail for older adults in nursing homes - [link](#)

JAMA IM: Semaglutide vs Tirzepatide for Weight Loss in Adults with Overweight or Obesity - [link](#)

JACCP: Impact of pharmacist-led discharge medication reconciliation on error and patient harm prevention at a large academic medical center - [link](#)

JPPR: Implementation of hospital electronic medical record Patient Friendly Medication Lists and Interim Medication Administration Charts - [link](#)

JPPR: Intravenous amoxicillin-clavulanic acid: prescribing practices in Australian hospitals - [link](#)

Lancet ID: Comparative effectiveness of combination therapy with nirmatrelvir–ritonavir and remdesivir versus monotherapy with remdesivir or nirmatrelvir–ritonavir in patients hospitalised with COVID-19: a target trial emulation study - [link](#)

MDPI: Factors Determining Quality of Drug Information by Hospital Pharmacies—Results from Five-Year Annual Quality Assessment - [link](#)

MJA: Living evidence syntheses: the emerging opportunity to increase evidence-informed health policy in Australia - [link](#)

MJA: Out-of-pocket health care expenses for people with and without cancer, New South Wales, 2020: a cross-sectional study – [link](#) - [editorial](#)

NEJM: Anticipating the Next Pandemic - [link](#)

Pharmacotherapy: Consensus recommendations for use of long-acting antiretroviral medications in the treatment and prevention of HIV-1- [executive summary](#) - [link](#)

Pharmacotherapy: Update on the clinical applications of SGLTis- [link](#)

REPORTS AND PUBLICATIONS – AUSTRALIA

Agency for Clinical Innovation (ACI), NSW

The latest weekly Evidence Digest can be found [here](#)

AHHA

- Updated Position Statement: Equality for LGBTIQ+ people in health - [link](#)

- Update on Modernising My Health Record Review – [summary report](#)

Australian Commission on Safety and Quality in Health Care (ACSQHC)

- Australian Passive AMR Surveillance: Trends in macrolide resistance in Streptococcus agalactiae and Streptococcus pyogenes – 2006 to 2023 - [link](#)

Australian Institute for Health and Welfare (AIHW)

- Australia's health 2024 – [link](#) – [brief summary](#); Alcohol, tobacco & other drugs in Australia – [update](#)

- Health checks and follow-ups for Aboriginal and Torres Strait Islander people - [link](#)

PBS

- PBAC Public Summary Documents – March 2024 meeting - [5 July 2024](#)

TGA

- [Database](#) of section 19A approvals to import and supply medicines to address medicine shortages

- Australian prescription medicine decision summaries:

-- [Mirena](#) (levonorgestrel) intrauterine device - long-acting reversible contraceptive. The duration for use as a contraceptive has been extended from 5 years to 8 years

-- [Oxlumo](#) (lumasiran) for primary hyperoxaluria type 1 (PH1) in all age groups

-- [Amvuttra](#) (vutrisiran) for hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy

-- [Cibinqo](#) (abrocitinib) for moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy. Cibinqo can be used with/ without medicated topical therapies for atopic dermatitis

Victorian Institute of Forensic Medicine

- Clinical Communiqué Volume 11 Issue 2 [June 2024](#)

REPORTS AND PUBLICATIONS – INTERNATIONAL

All Wales Medicines Strategy Group

- Cytisine recommended for use within NHS Wales for smoking cessation - [link](#)

- [Nivolumab](#) not recommended for use within NHS Wales for first-line treatment of deficient mismatch repair / high microsatellite instability oesophageal and gastric cancer

Canadian Agency for Drugs and Technologies in Health

- Somatropin - [link](#)

- Trends in Public Drug Plan Expenditures for Patients With Crohn Disease and Ulcerative Colitis Initiating Targeted Immune Modulator Therapy - [link](#)

Care Quality Commission (UK)

- The safer management of controlled drugs: Annual update 2023 - [link](#)

electronic Medicines Compendium (eMC) (UK)

- [New products](#)

-- Lyfnua (gefapixant citrate) - selective antagonist of the P2X3 receptor for refractory or unexplained chronic cough in adults

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988

Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

ABN: 82 707 308 091

- Ocrevus (ocrelizumab) - new subcutaneous formulation for adults with relapsing forms of multiple sclerosis or early primary progressive multiple sclerosis. Patients currently receiving intravenous ocrelizumab may transition to this formulation
- Tolak (fluorouracil) - topical treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis (Olsen grade I and II) of the face, ears, and/or scalp in adults
- Uzpruvo (ustekinumab) - pre-filled syringe of biosimilar highly similar to Stelara for moderate to severe plaque psoriasis in adults and children aged ≥ 6 years, psoriatic arthritis (adults) and moderate to severely active Crohn's disease (adults)
- Yorvipath (palopegteriparatide) pre filled pen - prodrug of parathyroid hormone given once daily by subcutaneous injection, is licensed for the treatment of adults with chronic hypoparathyroidism
- Yuflyma (adalimumab) – 20mg prefill biosimilar for same indications as the originator Humira

Future Health

- Building new health system action to reduce obesity: Audit findings of Integrated Care Board Forward Plans - [link](#)

Health Foundation, UK

- What builds good health? - [link](#)

Homecare Association, UK

- Expecting the Unexpected: Homecare providers' views of hospital discharge - [link](#)

Medicines and Healthcare products Regulatory Agency (MHRA)

- MHRA approves vibegron to treat adult patients with Overactive Bladder Syndrome (OAB) - [link](#)
- Capivasertib approved to treat patients with advanced breast cancer - [link](#)
- Ocrelizumab approved as an injection to treat multiple sclerosis in adults - [link](#)

MIMS, UK

- MIMS summary: New once-daily fluorouracil cream launched for actinic keratosis - [link](#)

NHS England

- Children and young people diabetes toolkit - [link](#)
- Framework for managing the response to pandemic diseases - [link](#)

NHS Providers

- Making sense of health inequalities - [link](#)

NHS Scotland

- SMC completes initial assessment of the evidence for birch bark extract gel (Filsuvez®) for treatment of partial thickness wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in patients ≥ 6 months - [link](#)
- Accepted for use:
 - [Nivolumab with relatlimab](#) (Opdualag®) for first-line advanced melanoma in those aged ≥ 12 years
 - [Pembrolizumab](#) (Keytruda®) in combination with chemotherapy, for first-line HER2-negative gastric or gastro-oesophageal junction adenocarcinoma in adults whose tumours express PD-L1
 - [Voretigene neparvovec](#) (Luxturna®) for vision loss due to inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations
- Accepted for restricted use:
 - [Empagliflozin](#) (Jardiance®) for chronic kidney disease in adults
 - [Follitropin delta](#) (Rekovelle®) for controlled ovarian stimulation in women undergoing assisted reproductive technologies
 - [Pegunigalsidase alfa](#) (Elfabrio®) for long-term enzyme replacement therapy in adults with a confirmed diagnosis of Fabry disease
- Not recommended:
 - [Pembrolizumab](#) (Keytruda®) in combination with trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with a CPS ≥ 1

National Institute for Health and Care Excellence (NICE) UK

- Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over ([TA986](#))
- NICE recommends Hemgenix for severe haemophilia B - [link](#)
- Need for treatment pauses challenged by migraine prevention data - [link](#)
- Improving mood reduces inflammation in inflammatory bowel disease - [link](#)

National Institute for Health and Care Research (NIHR)

- Emollient application from birth to prevent eczema in high-risk children: the BEEP RCT - [link](#)
- Devices for remote continuous monitoring of people with Parkinson's disease: a systematic review and cost-effectiveness analysis - [link](#)

Specialist Pharmacy Services NHS UK

- New product evaluations – [June 2024 update](#)

The King's Fund (UK)

- Realising the potential of integrated care systems - [link](#)

UK Health Security Agency

- Your guide to the RSV vaccine for older adults - [link](#)
- A guide to Respiratory syncytial virus (RSV) vaccination for pregnant women - [link](#)
- Respiratory syncytial virus (RSV) programme: information for healthcare professionals - [link](#)
- UKHSA encourages timely vaccination as whooping cough cases rise - [link](#)
- Immunisations for teenagers and young people - [link](#)

World Health Organisation (WHO)

- Establishing quality specifications for medicines, vaccines and in vitro diagnostics - [link](#)
- Recommendations for the treatment of Trichomonas vaginalis, Mycoplasma genitalium, Candida albicans, bacterial vaginosis and human papillomavirus (anogenital warts) - [link](#)
- WHO global action plan on promoting the health of refugees and migrants, 2019–2030 - [link](#)

MEDICATION SAFETY

electronic Medicines Compendium (eMC) (UK)

- Revised SPCs

- Bavencio (avelumab): information included on ADRs reported during treatment with other immune checkpoint inhibitors, which might also occur during treatment with avelumab
- Buvidal (buprenorphine): opioids can cause sleep-related breathing disorders, and dose reduction can be considered should this occur. Also, presence of traces of natural rubber & latex in product cannot be excluded, and there is a potential risk of allergic reaction in latex sensitive patients
- Camzyos (mavacamten): updated to remove the statement that bioequivalence between strengths has not been confirmed. The prohibition on the use of multiple capsules to achieve a prescribed dose has also been deleted
- Ceftriaxone: hypersensitivity reactions reported with all beta-lactam antibiotics; can also progress to Kounis syndrome (frequency unknown), a serious allergic reaction that can result in myocardial infarction
- Comirnaty (tozinameran) 12+ years, Omicron XBB.1.5 (raxtozinameran), Original/Omicron BA.1 (riltozinameran, tozinameran), Original/Omicron BA.4-5 (tozinameran, famtozinameran) mRNA vaccines updated to include information about, and safety data for, co-administration with Flu vaccine
- Dupixent (dupilumab) pre-filled pen for use in adult & paediatric patients (APPs) aged ≥2 years & pre-filled syringe in APPs aged ≥6 months. In children ≥12 years, dupilumab should be administered by/under supervision of adult & in children age 6 months to <12 years, by a caregiver
- Eviplera (emtricitabine, rilpivirine & tenofovir disoproxil) updated with warning/precaution on bone effects, and reduced bone mineral density has been added as a common potential ADR
- Glycopyrronium bromide: pregnancy & breastfeeding contraindication removed. Can cause thickening of secretions, which may increase risk of respiratory infection & pneumonia so it should be discontinued if pneumonia is present

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988

Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

ABN: 82 707 308 091

- Hydrea (hydroxycarbamide): may falsely elevate sensor glucose results from certain continuous glucose monitoring systems, which may lead to missed hypoglycaemic episodes and can also cause hypoglycaemia if sensor glucose results are relied upon to dose insulin
- Keytruda (pembrolizumab): pancreatic exocrine insufficiency and coeliac disease added as rare potential ADRs
- Luforbec (beclometasone dipropionate & formoterol fumarate): pharyngeal erythema (uncommon), increased blood pressure (uncommon), and decreased blood pressure (rare) added as ADRs
- Mekinist: atrioventricular block (including complete block) added as an ADR with frequency “not known” for mono therapy and “uncommon” for combination therapy with dabrafenib
- Non-Drowsy Sinutab (paracetamol, pseudoephedrine) updated to warn of risk of abuse; increased doses may ultimately produce toxicity, and continuous use can lead to tolerance resulting in an increased risk of overdosing. Recommended maximum dose and treatment duration should not be exceeded
- Ovex (mebendazole) Suspension: following oral administration, less than 10% of the dose reaches the systemic circulation (previously stated ~ 20%)
- OxyContin (oxycodone): may cause dysfunction & spasm of the Sphincter of Oddi, raising intrabiliary pressure & increasing risk of biliary tract symptoms & pancreatitis. Therefore, it must be administered with caution in patients with pancreatitis & biliary tract diseases
- Peyona (caffeine citrate): noting it is a clear, colourless, aqueous solution with a pH of 4.7 and an osmolality of 144 to 166 mOsm/kg
- Phenergan (promethazine) must not be used in children <6 years of age due to potential for fatal respiratory depression, psychiatric & central nervous system events. Also highlights that phenothiazines may potentiate the action of other depressants (e.g. opiates, alcohol)
- Phenoxymethylpenicillin Sugar Free should ideally be given half an hour before (or at least three [previously 2] hours after) a meal, and to note excretion of metabolites in human milk presents a risk of candidiasis and also of CNS toxicity due to prematurity of the blood brain barrier
- Prostag (leuprorelin): severe cutaneous adverse reactions reported including Stevens-Johnson syndrome and toxic epidermal necrolysis (unknown frequency), which can be life-threatening or fatal, & metabolic changes linked to GnRH agonist may also include fatty liver disease
- Revestive (teduglutide) for short bowel syndrome in those aged 4 months corrected gestational age and above (previously from 1 year and above): dosing and clinical trial information added
- Rifampicin products (Rifadin; Rifanah): caspofungin included as an interacting medicine; note that after two weeks of repeated administration of rifampicin, trough levels of caspofungin were 30% lower than in adult subjects who received caspofungin alone
- Rinvoq (upadacitinib hemihydrate): updated with long term safety and efficacy data up to week 104 from SELECT-AXIS 2 study for patients with non-radiographic axial spondyloarthritis
- Seroquel (quetiapine): serotonin syndrome added as an ADR. If concomitant treatment with other serotonergic agents is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases
- Sunitinib: hyperammonaemic encephalopathy added as a potential ADR of unknown frequency. Clinicians are advised to check ammonia levels in patients that develop unexplained lethargy or changes in mental status and treat as clinically appropriate
- Tafinlar (dabrafenib): peripheral neuropathy (including sensory and motor neuropathy) added as a common ADR
- Tecentriq (atezolizumab) injection: coeliac disease added as a rarely occurring ADR
- Tegretol (carbamazepine): maximum daily dose limited to 1200 mg per day for Tegretol Liquid
- Topamax (topiramate) new MHRA safety measures added, including a Pregnancy Prevention Programme, which must be fulfilled in women of childbearing potential, otherwise use would be contraindicated in this patient group
- Yentreve and Cymbalta (duloxetine) hard gastro-resistant capsules: neuroleptic malignant syndrome (NMS) may occur with duloxetine treatment, and that in its most severe form, serotonin syndrome can resemble NMS. Stress cardiomyopathy (Takotsubo cardiomyopathy) added as ADR

EMA

- Glatiramer acetate: anaphylactic reactions may occur months up to years after treatment initiation - [link](#)

- New EU recommendations for GLP-1 receptor agonists to minimise risk of aspiration and pneumonia aspiration during general anaesthesia or deep sedation - [link](#)

MIMS, UK

- New MIMS resource summarises pancreatin options amid supply shortages - [link](#)

Specialist Pharmacy Services NHS UK

- Clinical considerations for patients prescribed clozapine - [link](#)
- Managing the risks associated with patients prescribed clozapine - [link](#)
- Administration of contrast agents under a PGD by multiple HCPs - [link](#)
- Legal mechanisms and contrast agents - [link](#)
- Occupational health services explainer videos - [link](#)
- Preparing to use ustekinumab biosimilar - [link](#)

TGA

- Zactin Tabs (fluoxetine 20 mg dispersible tablets) shortage resolved - [link](#)

PAPERS OF INTEREST

Age and Ageing

- Inappropriate prescribing in older people: not only a patient safety issue but an avoidable source of environmental harm - [link](#)

American Journal of Emergency Medicine

- Efficacy of second-line anticonvulsant agents with adult status epilepticus: A systematic review and network meta-analysis - [link](#)

American Journal of Health-System Pharmacy (AJHSP)

- Impact of connected dispensing technology with advanced analytics in a multicenter health system - [link](#)
- Risk factors for treatment of asymptomatic bacteriuria in a rural health system - [link](#)
- Pharmacotherapy considerations for pediatric acute agitation management in the emergency department - [link](#)
- Central lines, aseptic batching services, and infection rates: A pharmacy-led initiative of intravenous tube priming within a NICU - [link](#)
- A call to action: Studying the shortened duration of ceftriaxone for inpatient management of acute uncomplicated cystitis - [link](#)
- Using quality improvement frameworks to develop, implement, and evaluate a novel ambulatory oncology pharmacy practice model: A descriptive example - [link](#)
- Exploring the therapeutic utility of the factor XIa inhibitor asundexian - [link](#)
- Mapping the next steps for critical care pharmacists - [link](#)
- A national survey of medication utilization for cardiac resuscitation in the emergency department: A survey of emergency medicine pharmacists - [link](#)
- From transthyretin cardiac amyloidosis diagnosis to tafamidis treatment: Association of drop-off with patient sociodemographic characteristics - [link](#)

Annals of Internal Medicine

- Comparative Effectiveness and Safety of Apixaban, Rivaroxaban, and Warfarin in Patients with Cirrhosis and Atrial Fibrillation: A Nationwide Cohort Study - [link](#)
- Effect of Acupuncture for Methadone Reduction: A Randomized Clinical Trial - [link](#)
- Best Practices in Caring for Seriously Ill Patients - [link](#)
- Glucagon-Like Peptide-1 Receptor Agonists and Risk for Suicidal Ideation and Behaviors in U.S. Older Adults with Type 2 Diabetes: A Target Trial Emulation Study - [link](#)

Arthritis & Rheumatology

- 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases - [link](#)

Australian Health Review

- Leveraging existing data to improve antimicrobial resistance-related mortality estimates for Australia - [link](#)

British Journal of Clinical Pharmacology

- Initiation of lipid-lowering therapy as primary prevention of cardiovascular disease in the elderly - [link](#)
- Optimizing anticoagulation therapy for in-hospital patients on direct oral anticoagulants: a single-centre modified Delphi study - [link](#)
- Antidepressant and antipsychotic prescribing in patients with type 2 diabetes in Scotland: A time-trend analysis from 2004 to 2021 - [link](#)
- Infringement of clinical pharmacist's authority - [link](#)
- Economic evaluations of therapeutic drug monitoring interventions in acute hospital-based settings: A systematic review - [link](#)
- Efficacy and safety of androgen receptor inhibitors for treatment of advanced prostate cancer: A systematic review and network meta-analysis - [link](#)
- Steroid–tacrolimus drug–drug interaction and the effect of CYP3A genotypes - [link](#)

British Journal of General Practice

- Breast cancer risk assessment for prescription of menopausal hormone therapy in women with a family history of breast cancer: an epidemiological modelling study - [link](#)
- Cost-utility analysis of molnupiravir for high-risk, community-based adults with COVID-19: an economic evaluation of the PANORAMIC trial - [link](#)
- Should I Take Aspirin? (SITA): randomised controlled trial of a decision aid for cancer chemoprevention - [link](#)

British Medical Journal (BMJ)

- State of the Art Review: New and emerging treatments for major depressive disorder - [link](#)
- Novo Nordisk failed to disclose £7.8m in payments to doctors and others over three years - [link](#)
- Does frailty need a new name? - [link](#)
- Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration - [link](#)

BMJ Open

- Are adverse events higher among patients with acute optic neuritis prescribed glucocorticoids? A retrospective, longitudinal cohort study - [link](#)

BMJ Quality and Safety

- Frequency and preventability of adverse drug events in the outpatient setting - [link](#)
- Components of pharmacist-led medication reviews and their relationship to outcomes: a systematic review and narrative synthesis - [link](#)
- Longitudinal cohort study of discrepancies between prescribed and administered polypharmacy rates: implications for National Aged Care Quality Indicator Programs - [link](#)

Circulation

- Apolipoprotein B: Bridging the Gap Between Evidence and Clinical Practice - [link](#)
- Effects of an Intervention to Improve Evidence-Based Care for People With Diabetes and Cardiovascular Disease Across Sex, Race, and Ethnicity Subgroups: Insights From the COORDINATE-Diabetes Trial - [link](#)
- Equitable Care for Hypertension: Blood Pressure and Patient-Reported Outcomes of the RICH LIFE Cluster Randomized Trial - [link](#)

Cochrane

- Adjunctive antimicrobial photodynamic therapy for treating periodontal and peri-implant diseases - [link](#)
- Treatment of uncomplicated hepatic cystic echinococcosis (hydatid disease) - [link](#)
- Bone-modifying agents for reducing bone loss in women with early and locally advanced breast cancer: a network meta-analysis - [link](#)
- Haloperidol (oral) versus olanzapine (oral) for people with schizophrenia and schizophrenia-spectrum disorders - [link](#)

Diabetes Care

- Sustained 3-Year Improvement of Glucose Control With Hybrid Closed Loop in Children With Type 1 Diabetes While Going Through Puberty - [link](#)
- Rational Pharmacotherapy in Type 2 Diabetes: Danish Data From 2002 to 2020 on Mortality, Diabetes- Related Outcomes, Adverse Events, and Medication Expenses - [link](#)

Drug and Therapeutics Bulletin

- Safety update: more on topical steroid severe adverse effects - [link](#)

EClinical Medicine

- 12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study - [link](#)

European Heart Journal

- Heart failure with preserved ejection fraction therapy: combining sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists - [link](#)
- Safety of treating acute pulmonary embolism at home: an individual patient data meta-analysis - [link](#)
- Thromboembolism after coronavirus disease 2019 vaccination in atrial fibrillation/flutter: a self-controlled case series study - [link](#)

European Journal of Hospital Pharmacy

- Taking care of caregivers: enhancing proper medication management for palliative care children with polypharmacy - [link](#)
- Cost-effectiveness of preoperative pharmaceutical care consultations: a 5-year analysis - [link](#)
- Clopidogrel-induced thrombotic microangiopathy: a case report - [link](#)
- Risk assessment of clinical trial protocols: a tool for hospital pharmacists to reduce human error in experimental drug management - [link](#)

Internal Medicine Journal

- Impact of hospital-administered extended-release naltrexone on readmission rates for patients with alcohol use disorder - [link](#)
- Evaluation of early fluoropyrimidine toxicity in solid organ cancer patients: a retrospective observational study in Australia - [link](#)

International Journal of Clinical Pharmacy

- Impact of medicine shortages on hospital practice: role of a multidisciplinary medicine shortages team - [link](#)
- The impact of codeine rescheduling on non-opioid analgesic use by people who regularly use codeine: a prospective cohort study - [link](#)
- The evolving role of pharmacists in depression care: a scoping review - [link](#)
- Anticholinergic burden and health-related quality of life among adult patients in a resource-limited setting: a cross-sectional study - [link](#)
- Anti-CGRP monoclonal antibodies in resistant migraine: preliminary real-world effectiveness and clinical predictors of response at two years - [link](#)
- Cost-effectiveness analysis of amivantamab plus chemotherapy for non-small cell lung cancer patients with epidermal growth factor receptor exon 20 insertions in the United States - [link](#)
- Authors' response to comments on "The efficacy of zuranolone versus placebo in postpartum depression and major depressive disorder: a systematic review and meta-analysis" - [link](#)

- A model for identifying potentially inappropriate medication used in older people with dementia: a machine learning study - [link](#)
- Cost avoidance of pharmacist-led deprescribing using STOPPFrail for older adults in nursing homes - [link](#)

JAMA

- Essential Tremor - [link](#)
- Patient page: What Are Food Allergies? - [link](#)

JAMA Cardiology

- Efficacy and Safety of Lerodalcibep in Patients With or at High Risk of Cardiovascular Disease: A Randomized Clinical Trial - [link](#)
- Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Male and Female Patients: A Secondary Analysis of the ADAPTABLE Randomized Clinical Trial - [link](#)
- Dose Reduction of Edoxaban in Patients 80 Years and Older With Atrial Fibrillation: Post Hoc Analysis of the ENGAGE AF-TIMI 48 Randomized Clinical Trial - [link](#)
- Dual vs Single Cardioversion of Atrial Fibrillation in Patients with Obesity: A Randomized Clinical Trial - [link](#)

JAMA Dermatology

- Dupilumab in Adults with Moderate to Severe Atopic Dermatitis: A 5-Year Open-Label Extension Study - [link](#)
- Immunotherapy for Advanced Skin Cancer in Kidney Transplant Recipients—The High-Risk Balancing Act - [link](#)

JAMA Internal Medicine

- Semaglutide vs Tirzepatide for Weight Loss in Adults with Overweight or Obesity - [link](#)

JAMA Network Open

- Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients with Type 2 Diabetes - [link](#)
- Interventions for Weight Management in Children and Adolescents Updated Evidence Report and Systematic Review for the US Preventive Services Task Force - [link](#)

JAMA Neurology

- Direct-Acting Oral Anticoagulants and Antiseizure Medications for Atrial Fibrillation and Epilepsy and Risk of Thromboembolic Events - [link](#)

JAMA Oncology

- Initial Management of BRAF V600E-Variant Anaplastic Thyroid Cancer: The FAST Multidisciplinary Group Consensus Statement - [link](#)

JAMA Ophthalmology

- Risk of Non-arteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide - [link](#)

J Am Coll Clin Pharm

- Impact of pharmacist-led discharge medication reconciliation on error and patient harm prevention at a large academic medical center - [link](#)

Journal of Clinical Oncology

- Denosumab Prevents Bone Loss and Microarchitectural Deterioration in Premenopausal Women with Breast Cancer Receiving Estradiol Suppression Therapy: A Randomized Controlled Trial - [link](#)

Journal of Pharmacy Practice and Research (JPPR)

- Sepsis call emergency department pharmacist service: a single healthcare network cohort study - [link](#)
- Pharmacist's role in influenza immunisation: a scoping review - [link](#)

- Implementation of hospital electronic medical record Patient Friendly Medication Lists and Interim Medication Administration Charts - [link](#)
- Intravenous amoxicillin-clavulanic acid: prescribing practices in Australian hospitals - [link](#)

Lancet

- The CONCORD–Lancet Global Commission on Cancer - [link](#)
- Chronic urticaria: unmet needs, emerging drugs, and new perspectives on personalised treatment - [link](#)

Lancet Diabetes & Endocrinology

- Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials - [link](#)
- Precision nutrition: a step too far? - [link](#)

Lancet Gastroenterology and Hepatology

- Portal vein thrombosis: diagnosis, management, and endpoints for future clinical studies - [link](#)

Lancet Haematology

- Diagnosis and management of Evans syndrome in adults: first consensus recommendations - [link](#)

Lancet Infectious Diseases

- Comparative effectiveness of combination therapy with nirmatrelvir–ritonavir and remdesivir versus monotherapy with remdesivir or nirmatrelvir–ritonavir in patients hospitalised with COVID-19: a target trial emulation study - [link](#)

Lancet Oncology

- Interpretable artificial intelligence to optimise use of imatinib after resection in patients with localised gastrointestinal stromal tumours: an observational cohort study - [link](#)
- NHS cancer services and systems—ten pressure points a UK cancer control plan needs to address - [link](#)
- Clinical benefit, reimbursement outcomes, and prices of FDA-approved cancer drugs reviewed through Project Orbis in the USA, Canada, England, and Scotland: a retrospective, comparative analysis – [link](#)

Lancet Respiratory Medicine

- Rethinking bronchiectasis as an inflammatory disease - [link](#)
- Nasal sprays and behavioural interventions compared with usual care for acute respiratory illness in primary care: a randomised, controlled, open-label, parallel-group trial - [link](#)

Molecular Diversity Preservation International (MDPI) – Pharmacy Journal

- Factors Determining Quality of Drug Information by Hospital Pharmacies—Results from Five-Year Annual Quality Assessment - [link](#)
- Adapting the Opening Minds Stigma Scale for Healthcare Providers to Measure Opioid-Related Stigma - [link](#)
- Exploring the Perceptions and Behaviours of UK Prescribers Concerning Novel Lipid-Lowering Agent Prescriptions: A Qualitative Study - [link](#)

Medical Journal of Australia

- National Hypertension Taskforce of Australia: a roadmap to achieve 70% blood pressure control in Australia by 2030 - [link](#)
- Living evidence syntheses: the emerging opportunity to increase evidence-informed health policy in Australia - [link](#)
- Out-of-pocket health care expenses for people with and without cancer, New South Wales, 2020: a cross-sectional study – [link](#) - [editorial](#)

New England Journal of Medicine

- Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer - [link](#)

- Nirsevimab and Hospitalization for RSV Bronchiolitis - [link](#)
- Malnutrition in Adults - [link](#)
- Anticipating the Next Pandemic - [link](#)

Neurology

- Efficacy of Atogepant in Chronic Migraine with and without Acute Medication Overuse in the Randomized, Double-Blind, Phase 3 PROGRESS Trial - [link](#)

Pediatrics

- Infantile and Very Early Onset Inflammatory Bowel Disease: A Multicenter Study - [link](#)
- Acetaminophen for Patent Ductus Arteriosus and Risk of Mortality and Pulmonary Morbidity - [link](#)
- The Importance of Timing When Evaluating PDA Treatment Outcomes - [link](#)
- Quality Improvement Interventions to Prevent Intraventricular Hemorrhage: A Systematic Review - [link](#)
- Immunogenicity and Safety of Extended-Interval 2-Dose Regimens of 9vHPV Vaccine - [link](#)
- Initiation of Buprenorphine Treatment of Opioid Use Disorder in Pediatric Emergency Departments - [link](#)

Pharmaceutical Journal

- Scottish government publishes prescribing guidance aiming to save millions of pounds - [link](#)

Pharmacotherapy

- Consensus recommendations for use of long-acting antiretroviral medications in the treatment and prevention of HIV-1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy, Canadian HIV and Viral Hepatitis Pharmacists Network, European AIDS Clinical Society, and Society of Infectious Diseases Pharmacists: An [executive summary](#) - [link](#)
- Update on the clinical applications of SGLTis: Insight to benefits beyond hypoglycemic and cardiorenal protection - [link](#)

Prescriber UK

- Antipsychotics: beyond dopamine - [link](#)
- Deprescribing in people living with frailty, multimorbidity and polypharmacy - [link](#)

Thorax

- Antibiotic pharmacokinetics in infected pleural effusions - [link](#)

WEBINARS & PODCASTS

Australian Prescriber Podcasts

- [Episode 167](#) – Diagnosis and management of obstructive sleep apnoea in adults

Purple Pen Podcast

- [PPP 163](#) - Monoclonal Antibodies

UPCOMING EVENTS

Australian Commission on Safety and Quality in Health Care (ACSQHC) - NMS 2024 – save the date, 19 November 2024 - [link](#)

Australian Healthcare and Hospitals Association (AHHA)

- Enabling hospitals and healthcare leaders to advance their sustainability journey, FREE WEBINAR, Thursday 25 July 16:00-17:00 AEST – [register](#)

Society of Hospital Pharmacists (SHPA)

- Medicines Management 2024 MM2024, Adelaide, 14-16 November 2024 - early-bird [registration](#) closes 11:59pm AEST Thursday 3 October 2024